Taysha Gene Therapies to Announce Q1 2024 Financials and Host May 14 Call

Taysha Gene Therapies, Inc., a biotechnology firm listed on Nasdaq under the ticker symbol TSHA, is dedicated to the development and commercialization of gene therapies targeting severe monogenic diseases of the central nervous system (CNS). Headquartered in Dallas, the company is at the forefront of pioneering adeno-associated virus (AAV)-based therapies.

Taysha's lead clinical program, TSHA-102, is currently in development to treat Rett syndrome. Rett syndrome is a rare neurodevelopmental disorder with significant unmet medical needs as there are no approved therapies that modify the disease's genetic root cause. This condition severely impacts patients and their caregivers, making the development of an effective treatment crucial.

The company's management team brings substantial experience in gene therapy development and commercialization. Drawing on this expertise, Taysha employs a clinically and commercially validated AAV9 capsid and a robust manufacturing process. This strategic approach aims to expedite the transition of treatments from research to clinical environments, ultimately bringing innovative therapies to patients more efficiently.

On May 14, 2024, Taysha Gene Therapies will report its financial results for the first quarter ending March 31, 2024. Following the financial report, the company will host a corporate update conference call and webcast at 4:30 PM Eastern Time. This event will provide stakeholders with insights into the company's progress and future plans.

Taysha's mission is rooted in the development of transformative medicines designed to address severe medical needs. The company’s relentless focus on innovation seeks to significantly improve the quality of life for patients affected by debilitating CNS disorders. For more information about their work and ongoing projects, interested parties are encouraged to visit their website.